Group 13Created with Sketch. GroupCreated with Sketch.
Created with Sketch. Created with Sketch.
  • Approach
  • Pipeline
  • Team
  • Partner
  • News & Events
  • Our Mission
  • Careers
  • Contact
Press Release
Recursion Pharmaceuticals Announces John Pereira, MBA as Chief Operating Officer
Press News & Events Home
SHARE
For Immediate Release
October 25, 2016

Recursion Pharmaceuticals, an emerging biotech in Salt Lake City, today announced that successful and serial technology entrepreneur and executive John Pereira, MBA, has joined the team as Chief Operating Officer. As former COO of Experticity, VP of AncestryDNA, and a leader of operational growth at Amazon in its earlier days, Mr. Pereira brings a wealth of experience in business management, operations, and technology strategy to Recursion’s rapidly growing business.

Chris Gibson, Ph.D., CEO of Recursion stated: “We are elated to bring John in as COO. His history of guiding businesses from startups to successes, and his extraordinary background in management, operations and strategy across industries is the perfect fit for us as we rapidly scale our complex business to meet the needs of our current and future partners, and ultimately to deliver on our mission to help bring 100 new treatments to patients in the coming years.”

The announcement of Mr. Pereira as COO follows closely on Recursion’s recent announcement of a successful $12.9M Series A funding round.

“John’s business acumen, track-record and his background in mathematics were a clear fit for our transformational approach to leveraging technology, big data, and artificial intelligence to change the way drug discovery is conducted,” said Blake Borgeson, Ph.D., CTO of Recursion.

Leading Silicon Valley deep technology Venture Firm Lux Capital led the recent Series A. “Folks of John’s technology and operational caliber simply don’t find their way to pharma often. This addition is indicative of Recursion’s multidisciplinary approach and hyper-focus on technology development and operations first and foremost,” said Lux’s Zavain Dar, who also sits on the Recursion Board. “We see this not as a standalone announcement, but as a continued call to arms for top technologists and entrepreneurs across the country that Recursion is leading the charge in AI and pharma. If you’re serious about disrupting biotech with technology, AI, and automation, then there is unequivocally no other place to be.”

“Recursion’s unique approach, at the intersection of data science, artificial intelligence, and biology is truly impressive and groundbreaking. I couldn’t be more excited to join the team and help build out a world-class organization focused on curing diseases with unprecedented efficiency,” said John Pereira.

About John Pereira, MBA Mr. Pereira is former COO of Experticity, a service that connects millions of industry experts with the world’s biggest brands and retailers to increase sales. Prior to Experticity, Mr. Pereira was Vice President of all Product, Marketing and Operational activities at AncestryDNA, Ancestry.com’s DNA business unit, where he built and launched the service, ultimately delivering on Ancestry’s unique combination of genomics with family history. Mr. Pereira has also served as Senior Manager of Operations Integration at Amazon.com, where he increased partnerships and oversaw operations of the Canadian fulfillment center, and a Naval Officer for the US Navy, where he led the Navigation and Administrative Department of the USS Reid, among other positions and duties. In addition to these positions, Mr. Pereira serves on the Board of Directors for Athletigen and the Advisory Board of Channel Signal. Mr. Pereira has a passion for new technology and a desire to break down traditional business barriers that pervades every aspect of his career.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals is an emerging biotechnology company based in Salt Lake City. Recursion combines experimental biology and bioinformatics with artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, oncology, and diagnostics. Recursion’s ultimate vision is to leverage technology to build a robust and reliable map of human cellular biology, which would enable a radical shift in the pace and scale at which new treatments could benefit patients. Learn more at www.recursionpharma.com, or connect on Twitter, Facebook, and LinkedIn.

Proudly
made in Utah.
  • Get to know us.
    • Approach
    • Pipeline
    • Our Mission
    • Team
  • Let’s connect.
    • Partner
    • Careers
  • What’s new?
    • Press Releases
    • Blogs and Publications
    • Events
    • Press Kit
We’re social creatures:
Recursion Pharmaceuticals, Inc.
41S Rio Grande Street
Salt Lake City, UT 84101
phone: (385) 269-0203
fax: (801) 821-2872
email: info@recursionpharma.com